Polynucleotides in Aesthetics: What the Evidence Says
A polynucleotide injectable is a gel of short, purified DNA fragments, usually prepared from a marine source, placed into the skin with a fine needle. It is sold as a skin-quality treatment rather than a filler, and it arrived through clinics and social platforms well ahead of the studies that would ordinarily support it. What is established about the material is narrow and mostly chemical: what it is made of, and that it is broken down and cleared over time. What is not established is the part the marketing is built on — that it repairs DNA, that it regenerates tissue, that its long-term behaviour is known. The published work behind the skin-quality, under-eye and hair claims is small, short and concentrated in a few centres. This site grades each claim separately and states where the product sits on the device route rather than the drug route, because that difference is a fact about regulation rather than about the material.
Chongqing West District Hospital, a tertiary general hospital in Jiulongpo District, Chongqing. This is a review of published evidence and regulation, not medical advice, and it is not a recommendation for or against any treatment.
How claims are graded here
Every claim on this site is placed in one of three groups, and the group matters more than the wording. Established means the claim follows from evidence that is consistent, replicated and reflected in how the material is regulated or described: that the product is a purified DNA-fragment gel of marine origin, and that it is broken down and cleared over time, sit here, because they are statements about a material rather than about a result. Emerging or limited means there is a mechanism, a signal and some small studies, but not the kind of evidence that establishes an effect — the skin-quality, under-eye and hair claims all sit here, and the honest description of each is that a small study reported a change. Not supported means the claim is made confidently and the evidence does not carry it, usually because the study that could test it has not been done in living skin, or because the wording describes a mechanism rather than a measurement. The reason for grading rather than simply reporting is that all three groups are written in the same confident register: “it repairs DNA” and “it supports the skin” are phrased identically, and neither is a finding. Where the evidence is thin this review says so, and where the only studies are small and come from few centres it says that too, because the size and independence of a study is the most useful thing a reader can know about it.
The device route and the drug route ask different questions
An injectable that produces an effect in the body is ordinarily assessed as a medicine, and that assessment asks for evidence of efficacy as well as of safety: trials showing that the treatment does something measurable in people. Some polynucleotide products have instead been placed on the market through a device route, where what is assessed is the safety of a material and whether it performs as described, and in some markets there is no injectable authorisation for these products at all. The same material can therefore be a lawfully marketed device in one country, an unauthorised injectable in a second and absent from a third, and that difference is a fact about regulation rather than about the material. Three things follow for a reader. The first is that a device registration is not a finding that the treatment works, and it was never asked to be one. The second is that a claim permitted under a device registration may be unlawful where the product is sold as a cosmetic, so the material a reader meets online often describes the most permissive market it is sold in. The third is that status is checkable: the register, the label and the certificate are documents rather than opinions, and asking to see them is a reasonable request. Where a page offers no regulatory status for a product, the honest reading is that there is none to offer.
What the evidence does establish
These are the claims that survive scrutiny. Each is stated with its own limit rather than as a general reassurance, and most of them are statements about a material rather than about a result.
The product is a defined material
Established. A polynucleotide injectable is a gel carrying short, purified DNA fragments, usually prepared from a marine source, and the fragments are short enough that they cannot carry genetic information. That the material is broken down and cleared over time is likewise a statement about the substance rather than about what it does.
Skin quality moves in a favourable direction in small studies
Limited. Several small randomised studies have reported changes in measured hydration, elasticity and roughness after a course of treatment, usually assessed with instruments. The limits are consistent across them: small groups, follow-up measured in months rather than years, work from a small number of centres, and a substantial share of it supported by the companies selling the material.
Under-eye appearance changes in some participants
Limited. Studies of the thin skin under the eye report changes in dark circles and skin quality in some participants, with results that vary between studies. Dark circles have several possible causes, including pigment, visible vessels and a shadow cast by a fat pad, and a study reporting an average change in a small group cannot say which cause was present in whom.
There is an early signal in hair thinning
Emerging. Small trials in pattern hair thinning have reported changes in hair counts and in measured hair diameter over short periods. The groups are small enough that a few participants moving in either direction changes the average, and hair growth responds unusually strongly to expectation, which makes an uncontrolled result very hard to read. This is a signal worth following, not a finding.
Short-term tolerance is the best-supported safety statement
Limited. In the studies that exist, and over the periods they cover, the material is generally tolerated, with the injection-site reactions that belong to any injectable into the skin. That is the whole of the safety statement the published work carries, and it says nothing about what happens over years, because no one has followed treated people for long enough to describe it.
Claims the evidence does not carry
These claims are common in this product class, and none of them is supported. Naming them is the most useful thing this review does, because they are written in the same confident register as the findings above.
That it repairs DNA in your skin
Not supported. DNA repair is a set of processes a cell performs on its own genetic material using its own enzymes, and it is not something that can be supplied in a syringe. No published study in living human skin has shown that injected DNA fragments alter the repair capacity of the tissue around them. The name describes the syringe, not the biology.
That it regenerates tissue
Not supported. Nothing published in living human skin shows that an injected polynucleotide causes new tissue to form in a way that could be measured against a control. Regeneration is a word from biology that has been adopted here as a category name, and a category name is not a finding. The same caution applies to the word repair.
That collagen stimulation is a demonstrated effect
Not an approved claim, and emerging at best. There is laboratory work suggesting that the material provokes a local tissue response, and it is a reasonable hypothesis. A laboratory mechanism is not living skin, and the step between the two is precisely the step that has not been taken. Where the word collagen appears, ask what was measured.
That long-term safety has been established
Not supported, and described in the asset as no long-term data. The material is intended to be broken down and cleared, which is presented as inherently safer. That is a reasoned argument rather than a dataset: it may turn out to be right, and no cohort has been followed long enough to show that it is. Unmeasured is not the same as reassuring.
That a device registration proves the effect
Not supported. A device route assesses a material for safety and performance and does not ask for evidence that the treatment changes anyone's skin. The registration is real; the claim attached to it is simply not covered by it. Where a product's status is offered as proof of effect, the two things have been merged.
What the risks are, stated plainly
The risks divide into those shared with every injectable and those that follow from what the material is. The shared ones are the familiar list: bruising, swelling, tenderness and a small risk of infection at the injection site, and, rarely, an event involving a blood vessel in the face, which is a serious occurrence and the reason these injections belong with a clinician who can recognise and manage one. The specific ones follow from the material itself. It is derived from a marine source, so an allergy question exists and there is no straightforward test that predicts a reaction. It is intended to provoke a response in the tissue, so nodules and granulomas are recognised for materials of this kind, and a granuloma is harder to deal with than an unwanted filler, which can at least be dissolved. And its behaviour over years is not known: the class has not been in aesthetic use long enough for a long-term cohort to exist, so the accurate description of long-term safety is that it is unmeasured rather than that it is good. There is also a risk that belongs to the decision rather than to the needle. Skin quality and under-eye appearance fluctuate with sleep, hydration, season and the hour, so a change after a course cannot easily be attributed to the treatment by the person who received it. Anyone paying for a course is buying an effect they will not be able to separate from the ordinary variation of their own face.
What else is on the table, including doing nothing
Doing nothing is the first alternative and is worth naming, because the appearances this product class targets change on their own, and a course of injections is a repeated commitment rather than a single decision. For skin texture specifically, a prescription topical retinoid with consistent sun protection is the best-evidenced thing available, costs a fraction of an injectable course and needs no needle. Where the goal is volume rather than surface, the alternatives are different in kind. A hyaluronic acid filler occupies a space, has a long published record and can be dissolved if the result is wrong, which is a property no polynucleotide product shares. The collagen-stimulating injectables have larger and longer published follow-up than this class does, and they carry their own risks and their own limits. Energy-based skin treatments and microneedling reach a similar goal by other means, with different evidence and different downtime. Where an under-eye shadow is cast by a fat pad, or where the darkness is pigment or visible vessels, none of these changes the cause, and an operation or a different treatment is the honest answer. Which of them applies, if any, depends on what is actually producing the appearance a person wants to change, and this review does not answer that for anyone.
How this review is kept current
This subject moves on three clocks at once, and they are worth separating. The evidence moves slowly: the studies that exist are small and recent, and the studies that could settle the open questions would take years to run. Regulation moves faster, because a product’s route to market can change with no new research being published at all, and a status that was accurate when a page was written can be out of date within a year. The marketing moves fastest of all, which is why a phrase such as DNA repair can be everywhere before a single study in living skin has tested it, and can remain everywhere long afterwards. This review is therefore dated and revisited on a short cycle, and the review covers three things rather than one. The first is whether any claim has moved between the three grading groups, in either direction, because a claim can become supported as well as cease to be. The second is regulatory status, since a change of route is a checkable fact a reader is entitled to have current. The third is whether the evidence base has changed in kind, because a further small study is a different event from a design that can actually test the claim. Where this review is wrong, the correction is made to the page itself rather than noted elsewhere, and the date of the most recent review appears on every page.
Claims about polynucleotide injectables, set against the evidence
Every row is a claim you are likely to meet, placed against what the evidence supports and what regulators have actually done about it. Evidence and regulatory status are two separate columns because they answer two separate questions.
The evidence guides
Each guide answers one question about the claim rather than about a treatment. Read the two or three that match what you are trying to establish.
What Polynucleotide Injectables Actually Are
A purified DNA-fragment gel of marine origin, injected for skin quality rather than volume: what the material is, and what the name does not say.
Read the guide →Why Polynucleotide Injectables Became Popular So Quickly
A product class that reached clinics and social platforms years ahead of its own literature, and what that sequence means for a reader weighing a claim.
Read the guide →The DNA Repair Claim, Examined
The name invites a mechanism that no study in living skin has demonstrated. Where the repair claim comes from, and how to test it in a sentence.
Read the guide →Regulatory Status of Polynucleotide Injectables
Why the same material can be a registered device in one market and an unauthorised injectable in another, and what each regulatory route actually asks.
Read the guide →What the Evidence Shows for Polynucleotides
The skin-quality, under-eye and hair claims graded separately, with the size, length and funding of the studies behind each one stated alongside the finding.
Read the guide →What Polynucleotides Have Not Been Shown to Do
Tissue regeneration, DNA repair and lasting change are asserted rather than demonstrated here, and each of those claims fails for a different reason.
Read the guide →A question about the polynucleotide evidence?
This site is an evidence review rather than a booking page, and it does not recommend for or against treatment or offer an assessment in relation to anything it describes. If you have a question about this review, or about your own care, contact the team and ask.
Frequently asked questions
What is a polynucleotide injectable, in plain terms?
A gel of short, purified DNA fragments, usually prepared from a marine source, placed into the skin with a fine needle. The fragments are short enough that they cannot carry genetic information, and the material is intended to be broken down and cleared by the body over time. That much is a chemistry question and is reasonably well settled.
Does it repair DNA in the skin that receives it?
No published study in living human skin has shown that it does. DNA repair is something a cell does for itself, using enzymes it already has, and it is not something that can be supplied in a syringe. The name describes the contents of the syringe rather than an effect on your cells, and the two have been allowed to merge.
Is it a filler?
No. A filler occupies a space and its result is seen as volume or contour, and a hyaluronic acid filler can be dissolved if the outcome is wrong. A polynucleotide injectable is intended to change how skin behaves, leaves no volume, and has no dissolving agent. They are different categories rather than different versions of one treatment.
Why can the same injectable be a device in one market and unauthorised in another?
Because the product took a different regulatory route in each market, and the routes ask different questions. A device route assesses the safety and performance of a material; a medicine route also asks for evidence of efficacy. Regulatory status is a fact about regulation rather than about the material, and it can change with no new research published.
How strong is the evidence behind it?
Small and short. The skin-quality claim rests on several small randomised studies with follow-up measured in months; the under-eye claim on studies with mixed results; the hair claim on the smallest trials of the three. Much of the work comes from a few centres and a substantial share is supported by the companies selling the material.
What is known about its long-term effects?
Very little, and the honest description is that the long-term behaviour is unmeasured rather than established. The class has not been in aesthetic use long enough for a cohort to have been followed for the years it would take to describe it. A material that is broken down and cleared is presented as inherently safer, which is a reasoned argument rather than a dataset.
Part of Injectables — 18 sites on this topic